Yasuyuki Naitoh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yasuyuki Naitoh has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Tsuneharu Miki
Departments of Translational Cancer Drug Development and Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan
5 shared publications - Kazumi Kamoi
Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan
4 shared publications Yasuhiro Yamada
Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan
4 shared publicationsFumiya Hongo
Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan
3 shared publications- Fumiya Hongo
Department of Urology Kyoto Prefectural University of Medicine Kyoto Japan
3 shared publications - Koji Okihara
Kyoto Prefectural University of Medicine, Kyoto, Japan
3 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 4 (10)
Propensity Score–Matched Comparison of Laparoscopic Transvesical Ureteral Reimplantation and Intravesical Open Ureterocystoneostomy for Primary Vesicoureteral Reflux: A Multicenter Study in Japan
Purpose: The aim of this study was to assess the real-world perioperative safety and reoperation risk of laparoscopic transvesical ureteral reimplantation (TVUR), using intravesical open ureterocystoneostomy as a reference procedure, in patients with primary vesicoureteral reflux (VUR). Materials and Methods: We retrospectively reviewed patients with primary VUR who underwent laparoscopic TVUR or intravesical open ureterocystoneostomy in Japan (2012-2022). Laparoscopic TVUR was defined as a laparoscopic intravesical (vesicoscopic) transvesical approach; robot-assisted intravesical procedures were excluded. Propensity score matching was performed using age, sex, height, weight, bilaterality, duplex ureter, ureterocele, and maximum VUR grade. The primary outcome was reoperation. Secondary outcomes included operative time, catheter removal, hospital stay, and complications. Results: Among 1330 patients (laparoscopic TVUR: n = 514; intravesical open ureterocystoneostomy: n = 816), 868 were matched (434 per group). Laparoscopic TVUR required longer operative time (median [interquartile range]: 262 [220-321] vs 182 [151-229] min; P < .001) but was associated with earlier catheter removal (3 [2-5] vs 6 [3-7] days; P < .001) and shorter hospitalization (5 [3-7] vs 7 [5-9] days; P < .001). Intraoperative and postoperative complications were more frequent with laparoscopic TVUR (4.4% vs 0.5% and 12.4% vs 4.1%, respectively; P < .001). Urinary peritonitis occurred only after laparoscopic TVUR. Reoperation was more common in this group (2.8% vs 0.7%; hazard ratio: 3.74, 95% confidence interval: 1.05-13.24; P = .041). Conclusions: In this multicenter propensity score–matched cohort of patients with primary VUR, laparoscopic TVUR was associated with earlier catheter removal and shorter hospitalization but higher complication and reoperation rates than intravesical open ureterocystoneostomy, underscoring the importance of careful patient selection and meticulous technique.
- 1 October 2026
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 4 (10)
Open AccessPropensity Score–Matched Comparison of Laparoscopic Transvesical Ureteral Reimplantation and Intravesical Open Ureterocystoneostomy for Primary Vesicoureteral Reflux: A Multicenter Study in Japan
Purpose: The aim of this study was to assess the real-world perioperative safety and reoperation risk of laparoscopic transvesical ureteral reimplantation (TVUR), using intravesical open ureterocystoneostomy as a reference procedure, in patients with primary vesicoureteral reflux (VUR). Materials and Methods: We retrospectively reviewed patients with primary VUR who underwent laparoscopic TVUR or intravesical open ureterocystoneostomy in Japan (2012-2022). Laparoscopic TVUR was defined as a laparoscopic intravesical (vesicoscopic) transvesical approach; robot-assisted intravesical procedures were excluded. Propensity score matching was performed using age, sex, height, weight, bilaterality, duplex ureter, ureterocele, and maximum VUR grade. The primary outcome was reoperation. Secondary outcomes included operative time, catheter removal, hospital stay, and complications. Results: Among 1330 patients (laparoscopic TVUR: n = 514; intravesical open ureterocystoneostomy: n = 816), 868 were matched (434 per group). Laparoscopic TVUR required longer operative time (median [interquartile range]: 262 [220-321] vs 182 [151-229] min; P < .001) but was associated with earlier catheter removal (3 [2-5] vs 6 [3-7] days; P < .001) and shorter hospitalization (5 [3-7] vs 7 [5-9] days; P < .001). Intraoperative and postoperative complications were more frequent with laparoscopic TVUR (4.4% vs 0.5% and 12.4% vs 4.1%, respectively; P < .001). Urinary peritonitis occurred only after laparoscopic TVUR. Reoperation was more common in this group (2.8% vs 0.7%; hazard ratio: 3.74, 95% confidence interval: 1.05-13.24; P = .041). Conclusions: In this multicenter propensity score–matched cohort of patients with primary VUR, laparoscopic TVUR was associated with earlier catheter removal and shorter hospitalization but higher complication and reoperation rates than intravesical open ureterocystoneostomy, underscoring the importance of careful patient selection and meticulous technique.
- Open Access
- 31 October 2024
- Published by Wolters Kluwer Health in International Journal of Surgery Protocols
- Vol. 28 (4) , 119-124
Exploratory trial of urethral submucosa injection therapy of deflux for stress urinary incontinence after radical prostatectomy
Background: After robot-assisted laparoscopic radical prostatectomy (RARP) for localized prostate cancer, post-operative stress urinary incontinence (SUI) impacts patient quality-of-life (QOL). A simple and less invasive treatment for SUI in these patients is urgently needed. Deflux is a viscous gel that consists of a mixture of sodium hyaluronate and dextranomer beads. It is administered by transurethral approach for the treatment of vesicoureteral reflux. In this study, we aim to establish a minimally invasive treatment for post-prostatectomy SUI through transurethral Deflux injection. Methods: We will perform a single-center, exploratory clinical trial to evaluate the safety and efficacy of transurethral injection of Deflux for SUI after RARP. Inclusion criteria are patients with SUI, a urine leakage volume between 15 and 500 g in a 24-h pad test, and those who use more than two pads per day. Five patients are scheduled to be enrolled in this pilot study. Deflux is injected endoscopically at the 3 o’clock and 9 o’clock positions in the submucosa until coaptation of submucosal bulking is achieved from both intraurethral sides. The primary endpoint is safety following Deflux injection. The secondary endpoint is efficacy on both SUI volume and patients’ QOL. Discussion: The importance of this clinical trial is to propose a new minimally invasive treatment option for male SUI patients after RARP.
- 31 October 2024
- Published by Wolters Kluwer Health in International Journal of Surgery Protocols
- Vol. 28 (4) , 119-124
Open AccessExploratory trial of urethral submucosa injection therapy of deflux for stress urinary incontinence after radical prostatectomy
Background: After robot-assisted laparoscopic radical prostatectomy (RARP) for localized prostate cancer, post-operative stress urinary incontinence (SUI) impacts patient quality-of-life (QOL). A simple and less invasive treatment for SUI in these patients is urgently needed. Deflux is a viscous gel that consists of a mixture of sodium hyaluronate and dextranomer beads. It is administered by transurethral approach for the treatment of vesicoureteral reflux. In this study, we aim to establish a minimally invasive treatment for post-prostatectomy SUI through transurethral Deflux injection. Methods: We will perform a single-center, exploratory clinical trial to evaluate the safety and efficacy of transurethral injection of Deflux for SUI after RARP. Inclusion criteria are patients with SUI, a urine leakage volume between 15 and 500 g in a 24-h pad test, and those who use more than two pads per day. Five patients are scheduled to be enrolled in this pilot study. Deflux is injected endoscopically at the 3 o’clock and 9 o’clock positions in the submucosa until coaptation of submucosal bulking is achieved from both intraurethral sides. The primary endpoint is safety following Deflux injection. The secondary endpoint is efficacy on both SUI volume and patients’ QOL. Discussion: The importance of this clinical trial is to propose a new minimally invasive treatment option for male SUI patients after RARP.
- 28 October 2022
- Published by Wiley in International Journal of Urology
- Vol. 30 (1) , 118-120
Novel surgical technique for orchiopexy of intra‐abdominal testis
- 28 October 2022
- Published by Wiley in International Journal of Urology
- Vol. 30 (1) , 118-120
Novel surgical technique for orchiopexy of intra‐abdominal testis
- 14 February 2016
- Published by Wiley in International Journal of Urology
- Vol. 23 (4) , 332-336
Transvesical laparoscopic surgery for double renal pelvis and ureter with or without ureterocele
Objective: To evaluate the performance of transvesical laparoscopic surgery for patients with complete double pelvis and ureter.Methods: A total of 10 patients were included in the present study: five had complete double pelvis and ureter with ureterocele (group A), and five did not have ureterocele (group B). Three small incisions of 5 mm were used, without incision in the lower abdomen. In group A patients, the ureterocele wall was resected, and two ureters were sufficiently detached as a combined ureteral complex. Ureterocele on the side of the bladder wall was sutured to the bladder neck, and the bladder wall was strengthened. According to the cross‐trigonal technique, ureterocystoneostomy was carried out in two ureters as a combined ureteral complex. In group B patients, two ureters were sufficiently detached, and ureterocystoneostomy was carried out as in group A.Results: In group A, the mean age was 13.4 years (range 2–34 years). The mean operation time was 304.6 min (242–346 min). In group B, the mean age was 16.6 years (range 2–48 years). The mean operation time was 207.8 min (150–249 min). There were no intraoperative and postoperative complications in both study groups.Conclusions: Transvesical laparoscopic surgery can be safely and effectively used in patients with double pelvis and ureter.
- 14 February 2016
- Published by Wiley in International Journal of Urology
- Vol. 23 (4) , 332-336
Transvesical laparoscopic surgery for double renal pelvis and ureter with or without ureterocele
Objective: To evaluate the performance of transvesical laparoscopic surgery for patients with complete double pelvis and ureter.Methods: A total of 10 patients were included in the present study: five had complete double pelvis and ureter with ureterocele (group A), and five did not have ureterocele (group B). Three small incisions of 5 mm were used, without incision in the lower abdomen. In group A patients, the ureterocele wall was resected, and two ureters were sufficiently detached as a combined ureteral complex. Ureterocele on the side of the bladder wall was sutured to the bladder neck, and the bladder wall was strengthened. According to the cross‐trigonal technique, ureterocystoneostomy was carried out in two ureters as a combined ureteral complex. In group B patients, two ureters were sufficiently detached, and ureterocystoneostomy was carried out as in group A.Results: In group A, the mean age was 13.4 years (range 2–34 years). The mean operation time was 304.6 min (242–346 min). In group B, the mean age was 16.6 years (range 2–48 years). The mean operation time was 207.8 min (150–249 min). There were no intraoperative and postoperative complications in both study groups.Conclusions: Transvesical laparoscopic surgery can be safely and effectively used in patients with double pelvis and ureter.
- 1 March 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (7_suppl) , 340
Preliminary study of combined use of PDD and NBI for detection for flat urothelial lesion.
340 Background: This prospective preliminary study is a first report to compare photodynamic diagnosis (PDD) with narrow band imaging (NBI) in the same patients with flat suspicious lesions of carcinoma in situ (CIS) of bladder. Methods: PDD was approved by the ethics committees of our institution for 10 patients with non muscle invasive bladder cancer. Between November 2012 and April 2013, 10 patients with abnormal cytology (class III or more) but undefined papillary mucosa underwent TURBT using PDD and NBI in same time. Each patient received 1.0g ALA hydrochloride (Cosmo Bio Co., Tokyo, Japan) dissolved in 50 mL water, and was given orally 3 hours before the TURBT. The bladder was mapped first under white light (WL), then under NBI, and subsequently under blue light (BL) in odd-numbered patients. The bladder was mapped first under WL, then under BL, and subsequently under NBI in even- numbered patients. Biopsies were carried out from all suspicious areas noting if NBI, PDD or both detected lesions. Random cold cup biopsies were performed from negative lesions of PDD and NBI. Results: The sensitivity and specificity of PDD for detection CIS were 1.00 and 0.714, and those of NBI were 0.75 and 0.814, respectively. There were no cancer and dysplasia in 43 lesions both PDD and NBI negative. Of 50 lesions with negative PDD, only 2 (4%) were dysplasia and there was no cancerous lesion. Of 60 lesions with negative NBI, 3 (5%) were cancer and 6 (10%) were dysplasia. The AUC for detection CIS in PDD, in NBI and in combined use of PDD and NBI were 0.869, 0.782 and 0.964, respectively. Conclusions: When both PDD and NBI were negative, the possibility of CIS might be very low. The usefulness of the combination of PDD with NBI was suggested in this study. [Table: see text]
- 1 March 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (7_suppl) , 340
Preliminary study of combined use of PDD and NBI for detection for flat urothelial lesion.
340 Background: This prospective preliminary study is a first report to compare photodynamic diagnosis (PDD) with narrow band imaging (NBI) in the same patients with flat suspicious lesions of carcinoma in situ (CIS) of bladder. Methods: PDD was approved by the ethics committees of our institution for 10 patients with non muscle invasive bladder cancer. Between November 2012 and April 2013, 10 patients with abnormal cytology (class III or more) but undefined papillary mucosa underwent TURBT using PDD and NBI in same time. Each patient received 1.0g ALA hydrochloride (Cosmo Bio Co., Tokyo, Japan) dissolved in 50 mL water, and was given orally 3 hours before the TURBT. The bladder was mapped first under white light (WL), then under NBI, and subsequently under blue light (BL) in odd-numbered patients. The bladder was mapped first under WL, then under BL, and subsequently under NBI in even- numbered patients. Biopsies were carried out from all suspicious areas noting if NBI, PDD or both detected lesions. Random cold cup biopsies were performed from negative lesions of PDD and NBI. Results: The sensitivity and specificity of PDD for detection CIS were 1.00 and 0.714, and those of NBI were 0.75 and 0.814, respectively. There were no cancer and dysplasia in 43 lesions both PDD and NBI negative. Of 50 lesions with negative PDD, only 2 (4%) were dysplasia and there was no cancerous lesion. Of 60 lesions with negative NBI, 3 (5%) were cancer and 6 (10%) were dysplasia. The AUC for detection CIS in PDD, in NBI and in combined use of PDD and NBI were 0.869, 0.782 and 0.964, respectively. Conclusions: When both PDD and NBI were negative, the possibility of CIS might be very low. The usefulness of the combination of PDD with NBI was suggested in this study. [Table: see text]
- Open Access
- 23 September 2014
- Published by Wiley in International Journal of Urology
- Vol. 22 (1) , 128-130
Percutaneous nephrolithotripsy and antegrade ureterolithotripsy in a 10-month-old infant with urinary stones in both kidney and ureter
- 23 September 2014
- Published by Wiley in International Journal of Urology
- Vol. 22 (1) , 128-130
Open AccessPercutaneous nephrolithotripsy and antegrade ureterolithotripsy in a 10-month-old infant with urinary stones in both kidney and ureter
- Open Access
- 13 August 2014
- Published by Springer Nature in BMC Research Notes
- Vol. 7 (1) , 1-5
Complete response of sunitinib therapy for renal cell cancer recurrence in the native kidney after renal transplantation: a case report
No case report has yet shown that sunitinib therapy for the postoperative recurrence of renal cancer in a native kidney after renal transplantation can achieve complete response (CR). A tumor was detected in the right native kidney of a 35-year-old Japanese male 10 years after renal transplantation. A tumor thrombus that reached the atrium was detected, which suggested cT3cN0M0. Because of the risk of perioperative complications, preoperative therapy with sunitinib was selected and 8 courses were administered. The size of the primary tumor was reduced by 33%, while that of the tumor thrombus was decreased by 39.5%. Right nephrectomy and removal of the tumor thrombus were then performed. Contrast-enhanced computed tomography (CT) four months after surgery suggested local relapse. Sunitinib was administered for 9 months, which led to complete response (CR). This study presented the case of sunitinib therapy for renal cancer in the native kidney after renal transplantation. The therapeutic efficacy and safety for such cases should be discussed.
- 13 August 2014
- Published by Springer Nature in BMC Research Notes
- Vol. 7 (1) , 1-5
Open AccessComplete response of sunitinib therapy for renal cell cancer recurrence in the native kidney after renal transplantation: a case report
No case report has yet shown that sunitinib therapy for the postoperative recurrence of renal cancer in a native kidney after renal transplantation can achieve complete response (CR). A tumor was detected in the right native kidney of a 35-year-old Japanese male 10 years after renal transplantation. A tumor thrombus that reached the atrium was detected, which suggested cT3cN0M0. Because of the risk of perioperative complications, preoperative therapy with sunitinib was selected and 8 courses were administered. The size of the primary tumor was reduced by 33%, while that of the tumor thrombus was decreased by 39.5%. Right nephrectomy and removal of the tumor thrombus were then performed. Contrast-enhanced computed tomography (CT) four months after surgery suggested local relapse. Sunitinib was administered for 9 months, which led to complete response (CR). This study presented the case of sunitinib therapy for renal cancer in the native kidney after renal transplantation. The therapeutic efficacy and safety for such cases should be discussed.
- 1 July 2014
- Vol. 60 (7) , 329-31
[A pediatric wilms' tumor presenting with a right renal injury].
We report a case of a pediatric Wilms' tumor presenting after a right renal injury. A 6-year-old girl presented to a nearby hospital with right back pain after a fall. An abdominal computed tomography (CT) scan revealed a right renal injury with active hemorrhaging. She was then referred to our hospital. There another CT scan and a magnetic resonance imaging (MRI) scan revealed the disappearance of the active hemorrhaging but also the presence of a large renal tumor. We performed a right nephrectomy. The renal tumor was diagnosed as a nephroblastoma. Considering dissemination by trauma, chemotherapy and radiation therapy were performed.
- 1 July 2014
- Vol. 60 (7) , 329-31
[A pediatric wilms' tumor presenting with a right renal injury].
We report a case of a pediatric Wilms' tumor presenting after a right renal injury. A 6-year-old girl presented to a nearby hospital with right back pain after a fall. An abdominal computed tomography (CT) scan revealed a right renal injury with active hemorrhaging. She was then referred to our hospital. There another CT scan and a magnetic resonance imaging (MRI) scan revealed the disappearance of the active hemorrhaging but also the presence of a large renal tumor. We performed a right nephrectomy. The renal tumor was diagnosed as a nephroblastoma. Considering dissemination by trauma, chemotherapy and radiation therapy were performed.
- Open Access
- 25 March 2014
- Published by Wiley in International Journal of Urology
- Vol. 21 (8) , 793-796
Laparoendoscopic single‐site versus conventional laparoscopic pyeloplasty: A matched pair analysis
Objective: To compare the outcomes of laparoendoscopic single‐site pyeloplasty versus those of conventional laparoscopic pyeloplasty.Methods: A total of 26 laparoendoscopic single‐site pyeloplasty cases carried out in University Hospital: Kyoto Prefectural University of Medicine, Kyoto, Japan, from 2008 to 2013 were compared with a control group of 26 age‐matched laparoscopic pyeloplasty cases carried out during the same study period.Results: The mean age of the patients was 20.4 years (range 1–56 years). Laparoendoscopic single‐site pyeloplasty was carried out on the right in nine cases and on the left in 17 cases. The operative time was 246 ± 68 min. Regarding the 14 pediatric patients, the mean age was 7.1 years (range 1–14 years). The operative time was 243 ± 49 min. As for the 12 adult patients, the mean age was 35.8 years (range 16–56 years). The operative time was 248 ± 86 min. The mean operative time of the control group in age‐matched laparoscopic pyeloplasty was 239 ± 51 min. Times were 229 ± 54 min for the pediatric patients and 253 ± 45 min for the adult patients. There was no significant difference in the operative time between the control group and the laparoendoscopic single‐site group for both adults and children. Blood loss was minimal, and no intraoperative and postoperative complications were observed in the 26 laparoendoscopic single‐site pyeloplasty cases.Conclusion: The present findings suggest that laparoendoscopic single‐site pyeloplasty can be used in both pediatric and adult patients, offering a superior cosmetic outcome than conventional laparoscopic pyeloplasty, and a lower degree of postoperative pain. A large‐scale prospective, randomized study is required to confirm these findings, and to define the future role of laparoendoscopic single‐site pyeloplasty.
- 25 March 2014
- Published by Wiley in International Journal of Urology
- Vol. 21 (8) , 793-796
Open AccessLaparoendoscopic single‐site versus conventional laparoscopic pyeloplasty: A matched pair analysis
Objective: To compare the outcomes of laparoendoscopic single‐site pyeloplasty versus those of conventional laparoscopic pyeloplasty.Methods: A total of 26 laparoendoscopic single‐site pyeloplasty cases carried out in University Hospital: Kyoto Prefectural University of Medicine, Kyoto, Japan, from 2008 to 2013 were compared with a control group of 26 age‐matched laparoscopic pyeloplasty cases carried out during the same study period.Results: The mean age of the patients was 20.4 years (range 1–56 years). Laparoendoscopic single‐site pyeloplasty was carried out on the right in nine cases and on the left in 17 cases. The operative time was 246 ± 68 min. Regarding the 14 pediatric patients, the mean age was 7.1 years (range 1–14 years). The operative time was 243 ± 49 min. As for the 12 adult patients, the mean age was 35.8 years (range 16–56 years). The operative time was 248 ± 86 min. The mean operative time of the control group in age‐matched laparoscopic pyeloplasty was 239 ± 51 min. Times were 229 ± 54 min for the pediatric patients and 253 ± 45 min for the adult patients. There was no significant difference in the operative time between the control group and the laparoendoscopic single‐site group for both adults and children. Blood loss was minimal, and no intraoperative and postoperative complications were observed in the 26 laparoendoscopic single‐site pyeloplasty cases.Conclusion: The present findings suggest that laparoendoscopic single‐site pyeloplasty can be used in both pediatric and adult patients, offering a superior cosmetic outcome than conventional laparoscopic pyeloplasty, and a lower degree of postoperative pain. A large‐scale prospective, randomized study is required to confirm these findings, and to define the future role of laparoendoscopic single‐site pyeloplasty.